Published • loading... • Updated
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Autoantibody-high participants had a 62.5% response rate, compared with 51.9% overall, supporting continued Phase 3 testing of the therapy.
- Johnson & Johnson announced on Wednesday that its Phase 2 JASMINE study showed nipocalimab sustained reductions in systemic lupus erythematosus disease activity through 52 weeks, measured by both SRI-4b and LLDAS endpoints.
- Designed to target the neonatal Fc receptor , nipocalimab reduces circulating pathogenic immunoglobulin G autoantibodies while preserving key immune functions, addressing the underlying cause of SLE.
- At Week 52, 53.6% of patients receiving nipocalimab 15 mg/kg achieved an SRI-4 response compared with 39.7% on placebo plus background medication; more patients also achieved Lupus Low Disease Activity State .
- Richard Furie, Chief of the Division of Rheumatology at Northwell, said "consistent improvements across established disease activity measures" support nipocalimab as a targeted approach for SLE patients.
- A Phase 3 study is currently underway to evaluate nipocalimab's potential to provide sustained disease control for adults with moderate-to-severe SLE, a debilitating autoantibody-driven disease.
Insights by Ground AI
46 Articles
46 Articles
Bennington Banner+24 Reposted by 24 other sources
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune functionResults demonstrated significant…
Daily Journal+19 Reposted by 19 other sources
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune functionNew exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody…
·Cherokee County, United States
Read Full Article
Coverage Details
Total News Sources46
Leaning Left5Leaning Right4Center18Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 18%
C 67%
15%
Factuality
To view factuality data please Upgrade to Premium
